1. Home
  2. JSPR vs CMPS Comparison

JSPR vs CMPS Comparison

Compare JSPR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jasper Therapeutics Inc.

JSPR

Jasper Therapeutics Inc.

HOLD

Current Price

$1.78

Market Cap

49.5M

Sector

Health Care

ML Signal

HOLD

Logo COMPASS Pathways Plc American Depository Shares

CMPS

COMPASS Pathways Plc American Depository Shares

HOLD

Current Price

$6.19

Market Cap

598.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JSPR
CMPS
Founded
2018
2020
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.5M
598.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
JSPR
CMPS
Price
$1.78
$6.19
Analyst Decision
Buy
Strong Buy
Analyst Count
12
8
Target Price
$25.60
$16.43
AVG Volume (30 Days)
3.8M
1.5M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.39
$2.25
52 Week High
$23.11
$7.13

Technical Indicators

Market Signals
Indicator
JSPR
CMPS
Relative Strength Index (RSI) 51.25 54.85
Support Level $1.61 $6.08
Resistance Level $1.93 $7.13
Average True Range (ATR) 0.21 0.41
MACD 0.02 0.06
Stochastic Oscillator 43.69 60.09

Price Performance

Historical Comparison
JSPR
CMPS

About JSPR Jasper Therapeutics Inc.

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Share on Social Networks: